The autoantibodies against C1q (anti-C1q) have been reported in patients with systemic lupus erythematosus (SLE). In the past decade, though there were increasing studies suggesting it is relatively specific in lupus nephritis (LN), its overall diagnostic value in LN has not been evaluated. The meta-analysis was conducted to quantitatively evaluate the diagnostic accuracy of autoantibodies against C1q in patients with LN, and to provide more precise evidence of a correlation between anti-C1q antibodies and activity of LN. We searched Medline, Embase and Cochrane databases and contacted authors if necessary. A total of 25 studies including 2,502 patients with SLE and 1,317 with LN met our inclusion criteria for this meta-analysis. Among all 25 studies, 22 studies were available for comparison between SLE with and without LN, and 9 studies compared anti-C1q between patients with active and inactive LN. Summary receiver operating characteristic (SROC) curve was used to summarize comprehensive test performance. The QUADAS tool was used to assess the quality of the studies. For the diagnosis of LN, the pooled sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of anti-C1q were 0.58 (0.56–0.61, 95% confidence interval [95% CI]), 0.75 (0.72–0.77, 95% CI), 2.60 (2.06–3.28, 95% CI), 0.51 (0.41–0.63, 95% CI), and 6.08 (3.91–9.47, 95% CI) respectively. The area under the SROC curve (AUC) was 0.7941. For comparison between active and inactive LN, the weighted sensitivity, specificity, PLR, NLR and DOR were 0.74 (0.68–0.79, 95% CI), 0.77 (0.71–0.82, 95% CI), 2.91 (1.83–4.65, 95% CI), 0.33 (0.19–0.56, 95% CI), and 10.56 (4.56–24.46, 95% CI) respectively. The AUC was 0.8378. In conclusion, this meta-analysis indicates that anti-C1q antibodies have relatively fair sensitivity and specificity in the diagnosis of LN, suggesting that the presence of anti-C1q antibodies may be a valuable adjunct for predicting LN and assessing renal activity.
BombackASAppelGB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol2010; 21: 2028–2035.
2.
DanilaMIPons-EstelGJZhangJVilaLMReveilleJDAlarconGS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford)2009; 48: 542–545.
3.
UwatokoSAotsukaSOkawaM. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol1984; 30: 104–116.
4.
PotlukovaEKralikovaP. Complement component c1q and anti-c1q antibodies in theory and in clinical practice. Scand J Immunol2008; 67: 423–430.
5.
TrouwLADahaMR. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther2005; 5: 243–251.
6.
GunnarssonIRonnelidJHuangYH. Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br J Rheumatol1997; 36: 32–37.
7.
ChenPCWangCRLiuMFChenFFLiangCC. Correlation between the renal C1q deposition and serum anti-C1q antibody: A potential role of anti-C1q antibody in lupus nephritis. Asian Pac J Allergy2002; 20: 223–227.
8.
MeyerOCNicaise-RolandPCadoudalN. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther2009; 11: R87–R87.
9.
Guerreiro De MouraCGPitangueira MangueiraCLSampaio CruzLASampaio CruzCM. Negative anti-C1q antibody titers may influence therapeutic decisions and reduce the number of renal biopsies in systemic lupus erythematosus. Nephron Clin Pract2011; 118: c355–c360.
10.
MoroniGTrendelenburgMDel PapaN. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis2001; 37: 490–498.
11.
MartoNBertolacciniMLCalabuigEHughesGRVKhamashtaMA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis2005; 64: 444–448.
12.
TrendelenburgMLopez-TrascasaMPotlukovaE. High prevalence of anti–C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant2006; 21: 3115–3121.
13.
MoroniGRadiceAGiammarresiG. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis2009; 68: 234–237.
14.
InesLDuarteCRodriguesFCunhaRSilvaJAP. Anti-C1q antibodies: A role in subsetting for lupus nephritis?Lupus2011; 20: 408–408.
15.
RavelliAWisnieskiJJRamenghiBBallardiniGZontaLMartiniA. IgG autoantibodies to complement C1q in pediatric-onset systemic lupus erythematosus. Clin Exp Rheumatol1997; 15: 215–219.
16.
KatsumataYMiyakeKKawaguchiY. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: A controlled study of 126 consecutive patients. Arthritis Rheum2011; 63: 2436–2444.
17.
AltintasNDTiryakiAOTutkakHDuzgunN. An analysis of the relationship between different autoantibodies and clinical findings in a group of Turkish patients with systemic lupus erythematosus. Gazi Medical Journal2008; 19: 126–132.
18.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
19.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
20.
WhitingPRutjesAWReitsmaJBBossuytPMKleijnenJ. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol2003; 3: 25–25.
21.
DevilleWLBuntinxFBouterLM. Conducting systematic reviews of diagnostic studies: Didactic guidelines. BMC Med Res Methodol2002; 2: 9–9.
22.
WalterSD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med2002; 21: 1237–1256.
23.
BowdenJTierneyJFCopasAJBurdettS. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol2011; 11: 41–41.
24.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58.
25.
Bernstein KA, Kahl LE, Balow JE, et al. Serologic markers of lupus nephritis in patients: Use of a tissue-based ELISA and evidence for immunopathogenic heterogeneity. Clin Exp Immunol 1994; 98: 60–5.
26.
Braun A, Sis J, Max R, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol 2007; 36: 291–8.
27.
Fang QY, Yu F, Tan Y, et al. Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol Dial Transplant 2009; 24: 172–8.
28.
Haseley LA, Wisnieski JJ, Denburg MR, et al. Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. Kidney Int 1997; 52: 1375–80.
29.
Jaekell HP, Trabandt A, Grobe N, et al. Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. Lupus 2006; 15: 335–45.
30.
Kozyro I, Perahud I, Sadallah S, et al. Clinical value of autoantibodies against C1q in children with glomerulonephritis. Pediatrics 2006; 117: 1663–8.
31.
Loizou S, Samarkos M, Norsworthy PJ, et al. Significance of anticardiolipin and anti-beta(2)-glycoprotein I antibodies in lupus nephritis. Rheumatology (Oxford) 2000; 39: 962–8.
32.
Mok CC, Ho LY, Leung HW, et al. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Transl Res 2010; 156: 320–5.
33.
Moura CG, Lima I, Barbosa L, et al. Anti-C1q antibodies: association with nephritis and disease activity in systemic lupus erythematosus. J Clin Lab Anal 2009; 23: 19–23.
34.
Norsworthy P, Theodoridis E, Botto M, et al. Overrepresentation of the Fcgamma receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. Arthritis Rheum 1999; 42: 1828–32.
35.
Oelzner P, Deliyska B, Funfstuck R, et al. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement. Clin Rheumatol 2003; 22: 271–8.
36.
Siegert CE, Daha MR, Tseng CM, et al. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 851–6.
37.
Siegert C, Daha M, Westedt ML, et al. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 1991; 18: 230–4.
38.
Sinico RA, Radice A, Ikehata M, et al. Anti-C1q autoantibodies in lupus nephritis: Prevalence and clinical significance. Ann Ny Acad Sci 2005; 1050: 193–200.
39.
Smykal-Jankowiak K, Niemir ZI, Polcyn-Adamczak M. Do circulating antibodies against C1q reflect the activity of lupus nephritis? Pol Arch Med Wewn 2011; 121: 287–95.
40.
Tan Y, Zhou W, Yu F, et al. Detection of anti-C1q antibodies and anti-C1q globular head domain antibodies in sera from Chinese patients with lupus nephritis. Mol Immunol 2009; 46: 2178–82.
41.
Wu FQ, Zhao Q, Cui XD, et al. C1q and anti-C1q antibody levels are correlated with disease severity in Chinese pediatric systemic lupus erythematosus. Rheumatol Int 2011; 31: 501–5.
42.
Zhang CQ, Ren L, Gao F, et al. Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China. Clin Rheumatol 2011; 30: 967–73.
43.
Trendelenburg M, Marfurt J, Gerber I, et al. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1999; 42: 187–8.
44.
Moroni G, Trendelenburg M, Del PN, et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490–8.
45.
Trendelenburg M. Anti-C1q antibodies as a diagnostic marker of proliferative lupus nephritis: Comment on the article by Katsumata et al. Arthritis & Rheumatism 2012; 64: 324–5.
46.
Horvath L, Czirjak L, Fekete B, et al. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001; 19: 667–72.
